Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 68001-499

13 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68001-499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table-1 (Table 1)

Table-1 (Table  1)
A data table labeled 'Table 1' showing the difference in number of suicidality cases per 1000 patients treated compared to placebo across age ranges. It lists increases for ages under 18 and 18-24, and decreases for ages 25-64 and 65 or older.*
FDA Label Image

Table-2 (Table 2)

Table-2 (Table  2)
Data table presenting the number and percentage of sustained elevations in supine diastolic blood pressure (SDBP) during premarketing studies of venlafaxine hydrochloride extended-release capsules. It compares incidences in major depressive disorder (75-375 mg/day) with other clinical trials (75-225 mg/day).*
FDA Label Image

Table-3 (Table 3)

Table-3 (Table  3)
A table presenting the incidence percentage of sustained elevations in systolic blood pressure (SDBP) in venlafaxine hydrochloride immediate-release tablet studies. The table categorizes the incidence based on daily venlafaxine dose ranges, showing increasing incidence percentages with higher doses.*
FDA Label Image

Table-4 (Table 4)

Table-4 (Table  4)
A data table presenting final on-therapy mean changes from baseline in supine systolic and diastolic blood pressure (mm Hg) for venlafaxine hydrochloride extended-release capsules compared to placebo. The results are shown by indication (Major Depressive Disorder or Other Clinical Trials), study duration, dose range (≤75 mg/day and >75 mg/day), and include supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP) values.*
FDA Label Image

Table -5 (Table 5)

Table -5 (Table   5)
A table presenting the incidence rates of insomnia and nervousness in placebo-controlled clinical trials of Venlafaxine Hydrochloride Extended-Release Capsules for Major Depressive Disorder and other trials. The table compares percentages of these symptoms occurring in patients taking venlafaxine versus placebo.*
FDA Label Image

Table (6)

Table (6)
A data table comparing the incidence of treatment-emergent adverse reactions in short-term placebo-controlled clinical trials for Venlafaxine Hydrochloride Extended-Release Capsules versus placebo in patients with major depressive disorder. The table lists body system preferred terms and percentage reporting reactions for each group, covering symptoms across various systems such as cardiovascular, digestive, nervous, respiratory, skin, special senses, and urogenital systems.*
FDA Label Image

Table (7)

Table (7)
Data table presenting the incidence rates of treatment-emergent adverse reactions reported in short-term placebo-controlled clinical trials for venlafaxine hydrochloride extended-release capsules versus placebo in social anxiety disorder patients. It categorizes adverse reactions by body system and compares percentages of subjects reporting each reaction for venlafaxine and placebo groups.*
FDA Label Image

Venlafaxine (Structure)

Venlafaxine (Structure)
Chemical structure diagram of venlafaxine hydrochloride, showing the molecular arrangement of the active ingredient venlafaxine including aromatic ring, hydroxyl group, and other functional groups.*
FDA Label Image

Symptoms (Medication guide)

Symptoms (Medication guide)
A text panel listing warning signs and symptoms that may require medical attention, including thoughts about suicide or dying, severe mood changes, panic attacks, insomnia, irritability, aggressive behavior, dangerous impulses, mania, unusual behavior changes, and visual problems such as eye pain or swelling.*
FDA Label Image

Venlafaxine Er Tab 37.5 (Venlafaxine Er Tabs 37.5.jpg.jpg)

Venlafaxine Er Tab 37.5 (Venlafaxine Er Tabs 37.5.jpg.jpg)
Label for Venlafaxine Extended-Release Tablets, 37.5 mg strength, in a package containing 30 tablets. The label indicates the product is Rx only and manufactured by Ascent Pharmaceuticals, Inc., for BluePoint Laboratories. Storage instructions and a note for dispensers to provide the Medication Guide are included.*
FDA Label Image

Venlafaxine Er Tab 75 (Venlafaxine Er Tabs 75)

Venlafaxine Er Tab 75 (Venlafaxine Er Tabs 75)
Label for Venlafaxine Extended-Release Tablets 75 mg by BluePoint Laboratories. The label includes the NDC code 68001-497-04, states the product is Rx only, and notes a package size of 30 tablets. It also provides storage instructions and manufacturer information as Ascent Pharmaceuticals, Inc.*
FDA Label Image

Venlafaxine Er Tab 80 (Venlafaxine Er Tabs 150)

Venlafaxine Er Tab 80 (Venlafaxine Er Tabs 150)
Label for Venlafaxine Extended-Release Tablets 150 mg oral dosage form by BluePoint Laboratories. The label identifies the product as prescription only, containing 30 tablets. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), and a barcode on the side. The label emphasizes dispensing with the attached Medication Guide.*
FDA Label Image

Venlafaxine Er Tab 225 (Venlafaxine Er Tabs 225)

Venlafaxine Er Tab 225 (Venlafaxine Er Tabs 225)
Label for Venlafaxine Extended-Release Tablets 225 mg by BluePoint Laboratories. The label includes NDC 68001-499-04, states it is Rx only, contains 30 tablets, and notes storage instructions. Manufactured by Ascent Pharmaceuticals, Inc. for BluePoint Laboratories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.